Heart Test Laboratories, Inc. (HSCS)
NASDAQ: HSCS · IEX Real-Time Price · USD
+0.010 (0.27%)
At close: Jul 23, 2024, 3:52 PM
-0.180 (-4.76%)
After-hours: Jul 23, 2024, 6:24 PM EDT

Company Description

Heart Test Laboratories, Inc., doing business as HeartSciences, is a medical technology company focuses on applying AI-based technology to an ECG to expand and improve an ECG's clinical utility.

It is developing AI-ECG solutions to be made available on a hardware agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers.

Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is designed to provide diagnostic information related to cardiac dysfunction.

The MyoVista also provides conventional ECG information in the same test. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Heart Test Laboratories, Inc.
Heart Test Laboratories logo
Country United States
Founded 2007
IPO Date Jun 15, 2022
Industry Medical Devices
Sector Healthcare
Employees 12
CEO Andrew Simpson

Contact Details

550 Reserve St, Suite 360
Southlake, Texas 76092
United States
Phone 682-237-7781
Website heartsciences.com

Stock Details

Ticker Symbol HSCS
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
IPO Price $4.25
CIK Code 0001468492
CUSIP Number 42254E104
ISIN Number US42254E1047
Employer ID 26-1344466
SIC Code 3842

Key Executives

Name Position
Andrew Simpson Chief Executive Officer, President and Chairman of the Board of Directors
Danielle Watson Chief Financial Officer and Treasurer
Mark T. Hilz Chief Operating Officer, Secretary and Director

Latest SEC Filings

Date Type Title
Jun 4, 2024 8-K Current Report
May 22, 2024 8-K Current Report
May 16, 2024 8-K/A [Amend] Current report
May 15, 2024 8-K Current Report
May 10, 2024 8-K Current Report
Mar 18, 2024 424B3 Prospectus
Mar 14, 2024 8-K Current Report
Mar 14, 2024 10-Q Quarterly Report
Mar 13, 2024 EFFECT Notice of Effectiveness
Mar 11, 2024 UPLOAD Filing